Research

Hormonal

Early rapid weight loss (≥15% by Week 24) with incretin-based obesity medications (tirzepatide or semaglutide) predicts greater overall efficacy (higher probability of achieving ≥25-30% total weight loss) without negatively impacting study completion rates, despite a numerically higher incidence of gastrointestinal and hepatobiliary adverse events.

If you are starting tirzepatide or semaglutide, losing weight quickly in the first few months is a good sign that you will likely achieve your long-term weight loss goals. While you may experience more stomach issues early on, this does not mean you will quit treatment. Monitor your health, manage side effects as needed, and trust that early rapid response is a positive predictor of success.

GoodQualifiesHIGH confidence
Although rapid responders experienced more gastrointestinal/hepatobiliary adverse events in both treatments, this did not affect rates of study treatment completion relative to non-rapid responders.
Louis J. Aronne et al. · The American Journal of Medicine · 2026

Why this rating

Based on a Phase 3b randomized controlled trial (SURMOUNT-5), though this specific finding is a post hoc analysis.

Source

Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis

Louis J. Aronne et al. · The American Journal of Medicine · 2026

DOI 10.1016/j.amjmed.2026.03.010

rct · n=740Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →